Virbac closed 2025 with €1.465 billion in revenue, up 7.9% organically at constant exchange rates and scope, with fourth-quarter sales rising 7.1% on the same basis. Growth was anchored by a 10.9% increase in companion animal and 6.1% in farm animal, underpinned by roughly five points of volume/mix and three points of price. The United States was the standout geography, with 14.7% organic growth, while IMEA, Latin America, and Europe all advanced 7.5–9.5%. The company guided to 5.5–7.5% organic revenue growth in 2026 and an adjusted operating margin near 17%, and it added a targeted bolt-on with Thyronorm, a feline hyperthyroidism therapy that will be commercialized directly in key markets. Alongside new launches like Ursolyx and Zenifel and the debut of Vikaly, a medicated petfood, Virbac is signaling where it intends to compete.
The strategic question is whether Virbac is graduating from dependable mid-cap operator to category shaper in specialty therapeutics and nutrition. The numbers suggest expanding pricing power and mix quality in companion animal, while Q4’s farm animal surge in Europe, driven by bluetongue vaccine and parasiticide demand, underscores the volatility of disease-led spikes and the premium on manufacturing agility. Execution—sustaining specialty pull-through in clinics, managing channel transitions, and smoothing outbreak-driven demand—will determine whether 2026’s margin ambition becomes a base or a ceiling.
This matters now because the center of gravity in animal health is tilting further toward premium companion care, where corporate vet groups, consolidated distributors, and pet insurers increasingly influence access. Virbac’s momentum in dental, dermatology, mobility, and behavior puts it squarely in the protocols and plan designs of large clinic networks. The move to market Thyronorm directly in the US, UK, Australia, and New Zealand, and to reclaim distribution in Europe over time, trades short-term transition friction for higher margins and tighter control of HCP engagement—while challenging erstwhile partners that also compete in adjacent categories. For farm animal customers, the European bluetongue response highlights how vaccine capacity and supply reliability have become strategic differentiators. In aquaculture, where Chile weighed on results, competitive intensity remains a headwind and may demand portfolio pruning or targeted reinvestment.
Industry-wide, Virbac’s “programmatic M&A” approach mirrors the broader healthcare shift toward bolt-ons that deliver immediate category depth and channel leverage rather than pipeline moonshots. The Thyronorm deal, though modest in absolute revenue, unlocks a high-need endocrine niche with recurring therapy, creates cross-sell with specialty ranges, and, in Europe, reconfigures the go-to-market away from partners toward direct ownership of the account. The introduction of a medicated petfood category is equally telling: the convergence of therapeutics and nutrition supports long-term adherence, opens the door to outcomes-based arguments with insurers, and elevates the role of Medical Affairs to generate real-world data and clinician guidance that validate use in everyday practice. FX headwinds, US tariff drag, and distributor changes are reminders that operational discipline must match portfolio ambition.
The next twelve months will test whether Virbac can compound double-digit growth in companion animal while normalizing Asia-Pacific and holding farm animal gains absent outbreak tailwinds. The integration of Thyronorm will show if direct distribution can accelerate specialty adoption without destabilizing legacy partnerships. The more provocative pivot, however, is Vikaly: if medicated nutrition earns inclusion in corporate clinic protocols and pet insurance formularies, does it become the next durable growth leg in animal health—or remain a niche that incumbents in therapeutics and petfood race to own?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
